OR WAIT null SECS
Terumo Blood and Cell Technologies and PhotonPharma announced a collaboration to develop a novel tumor-specific immunotherapy for solid tumors.
Terumo Blood and Cell Technologies, a medical device company, and PhotonPharma, a cancer immunotherapy developer, announced in an August 11, 2021 press release a memorandum of understanding (MOU) for collaboration to develop innocell, a novel tumor-specific immunotherapy for solid tumors.
The MOU/initial agreement details the following:
Since 2007, Terumo's mirasol has been used in select markets outside the United States. It was designed to reduce pathogen load and inactivate residual white blood cells in whole blood and blood components.